Atomi Financial Group Inc. Invests $291,000 in Natera, Inc. (NASDAQ:NTRA)

Atomi Financial Group Inc. bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 1,836 shares of the medical research company’s stock, valued at approximately $291,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Versant Capital Management Inc boosted its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares in the last quarter. Quarry LP lifted its holdings in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the last quarter. Covestor Ltd increased its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the period. GAMMA Investing LLC lifted its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Natera in the third quarter valued at approximately $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

NASDAQ NTRA opened at $167.61 on Monday. The business has a 50 day moving average price of $166.20 and a 200 day moving average price of $136.43. The company has a market capitalization of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. Natera, Inc. has a 1-year low of $62.96 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s revenue was up 63.9% on a year-over-year basis. During the same period last year, the company posted ($0.95) EPS. Sell-side analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on NTRA. Morgan Stanley increased their price target on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Guggenheim raised their price target on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. The Goldman Sachs Group lifted their target price on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Canaccord Genuity Group upped their price target on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $162.94.

Insider Activity

In other news, Director Gail Boxer Marcus sold 2,212 shares of the firm’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the sale, the director now owns 19,386 shares in the company, valued at $3,073,262.58. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John Fesko sold 669 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares of the company’s stock, valued at $18,217,063.20. The trade was a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 243,546 shares of company stock worth $40,338,829 over the last three months. 7.60% of the stock is currently owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.